Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04048343 | Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma | PHASE3 | COMPLETED | 65 | — | — | Jun 10, 2019 | Mar 18, 2021 | Jun 1, 2022 | 5 | Japan |
The number of subjects who experienced an AE during on-treatment period was summarised.
| Arm | Type | Description |
|---|---|---|
| Tezepelumab | EXPERIMENTAL | Tezepelumab: Tezepelumab subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| Biological: Experimental: Tezepelumab | DRUG | Tezepelumab subcutaneous injection every 4 weeks |
Inclusion Criteria: Age. 12-80 Documented physician-diagnosed asthma for at least 12 months Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months. Documented treatment with a total daily dose of either medium or high dose...